Clinical Trials/ Research
Paving the Way to Personalized Medicine for Cancer Patients
Agendia’s Clinical Trials Program
Agendia’s extensive clinical trials and research collaborations have produced numerous retrospective and prospective validation studies over the past twelve years which have enabled the successful commercialization of genomic microarray assays, such as the FDA-cleared 70-gene MammaPrint profile. Recently published studies further support the prognostic and predictive clinical utility of MammaPrint for early stage breast cancer patients, and large, multi-institutional clinical trials, such as MINDACT and ISPY-2, can be expected to expand the assay’s clinical importance and indications for use. Recently, the five year prospective results of the RASTER study were presented indicating that chemotherapy may be safely withheld in low risk breast cancer patients.
Currently, Agendia is enrolling institutions and cancer centers worldwide in its prospective PARSC trial for ColoPrint, an assay that evaluates recurrence risk in Stage II and III Colon Cancer patients, in the Multi Institutional Neo Adjuvant Therapy MammaPrint Project (MINT) trial for Neo- adjuvant patients, and in its Neo-adjuvant Breast Registry Symphony Trial NBRST (pronounced “in breast”,) and in the prospective observational, case-only, study of MammaPrint in patients with an Oncotype DX intermediate score (18-30) (PROMIS).
With Agendia’s state-of-the-art genomics laboratories in California and the Netherlands, the company is actively engaging academic centers, medical institutions and pharmaceutical companies in clinical trials collaboration opportunities, both in the USA and globally.